WebResults from HOST-REDUCE-POLYTECH-ACS Trial Reported at TCT Connect. NEW YORK – October 17, 2024 – A randomized clinical trial found that drug-eluting stents (DES) with … WebOct 17, 2024 · The aim of the HOST-REDUCE-POLYTECH-ACS (Harmonizing Optima Strategy for Treatment of coronary artery diseases – Comparison of Reduction of prasugrel or …
The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus ...
WebOct 10, 2024 · We aimed to investigate the safety and efficacy of a prasugrel-based dose de-escalation therapy. Methods: HOST-REDUCE-POLYTECH-ACS is a randomised, open-label, … WebFeb 4, 2024 · Overall, 23,637 patients (62.6%) presented as ACS, and the follow-up duration ranged from 12 to 24 months. Five trials evaluated P2Y12 inhibitor monotherapy compared with DAPT, two trials evaluated the switch from a potent P2Y12 inhibitor to clopidogrel, and one trial evaluated switching the dose of prasugrel from 10 to 5 mg. crystal in se
Randomized Trial Finds that Drug-Eluting Stents With Durable
WebOct 17, 2024 · HOST-Reduce-Polytech-ACS. PCI. biodegradable polymer. Hyo-Soo Kim. Up Next. Presentation TCT 2024. Monitoring in Heart Failure: Promise and Reality. Presenter: Liviu Klein. October 17, 2024. More slides + Presentation TCT 2024. ... The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents … WebAug 24, 2024 · Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial Authors WebJul 18, 2014 · Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients … dwight cook